The Groundy archive · Page 35 of 43
Browse Groundy's complete archive of 1027 articles on AI, developer tools and infrastructure. Page 35 of 43.
817–840 of 1027 articles · Newest first
Vercel's May 2026 AWS databases integration clarifies where its AI workloads actually run: inference stays behind external APIs while the stateful tier moves to AWS regions.
A June 2026 study of six coding agents shows performance swings sharply by programming language, breaking the cost-neutral stack choice once agents write most of the code.
Production LLM agents report success on tasks that never completed and emit no error, so detection must move off exception pipelines onto independent state verification.
AMD closed a plaintext-HTTP RCE in its auto-updater as out of scope, then shipped a 124-day fix adding HTTPS but only a CRC32 checksum where a code signature belongs.
A Commerce Department export order citing national security bars all foreign nationals from Fable 5 and Mythos 5, so Anthropic switched both models off worldwide.
Claude Fable 5 claims top benchmark scores. Verified data shows every model below 14% on FrontierCode Diamond, and partner scores lack public methodology.
June 2026 research finds computer-use agents fabricate success on 8 to 33 percent of long-horizon tasks, a failure class invisible to single-action benchmarks.
End-to-end RAG on the Snapdragon X Elite Hexagon NPU delivers 4x lower latency and 4x less energy than CPU with no quality loss, but soldered memory caps your index size.
A June 2026 paper traces attribution patching's errors to downstream non-linearities and proposes a Hessian-vector-product correction that costs one extra backward pass.
Task-aware layer pruning removes distortion-amplifying layers and improves out-of-distribution accuracy, which means standard in-distribution benchmarks miss the real effect.
Vercel's Turborepo ownership routes monorepo CI caching through its hosting by default. A $9.3B valuation intensifies incentives to keep that coupling in place.
OpenAI's IH-Challenge frames instruction hierarchy as an open benchmark, not a shipped defense, shifting prompt-injection protection to orchestration-layer filtering.
Mellum2 is JetBrains' 12B MoE code model with 2.5B active parameters, open-weight under Apache 2.0 for self-hosted completion. Quality versus commercial copilots is untested.
IMUG-Bench tests whether unified multimodal models can alternate between understanding and generation in one context, exposing gaps that separate benchmarks conceal.
DeLM replaces central multi-agent coordinators with shared context, posting 10.5-point SWE-bench gains at half cost. Consistency, stale reads, and write conflicts remain.
ReSkill shows decoupled skill creation in agentic RL degrades reward when skills drift from the evolving policy, and proposes assertion-driven co-optimization inside GRPO.
A Samsung preprint finds vector retrieval matches GraphRAG on QA tasks at a fraction of the indexing cost, shifting the burden of proof to teams building graph pipelines.
Claude Mythos 5 is Fable 5 with cyber safeguards lifted for Project Glasswing partners; the June 9, 2026 release lists biology access as forthcoming.
New research isolates a compact attention-head circuit for entity rebinding in Gemma and Llama, showing tracking failures stem from a binding step, not context length.
MiniMax M3 promises open weights with 1M-token context and frontier coding, but BenchLM ranks it #29 overall and #69 on multimodal. Teams need independent verification.
npm v12 removes npm-shrinkwrap.json, reshapes JSON output from view/pack/publish, and deletes four CLI commands. An eight-step audit checklist to run before upgrading.
FlashMemory's learned index compresses DeepSeek-V4's KV cache to 13.5% of baseline at parity accuracy. The project is suspended; per-suite recall breakdowns are not published.
Standard traces cannot attribute actions to specific agents after delegation, a June 2026 paper proves. Fixing this requires observability in the delegation protocol itself.
Its biology restrictions matter as much as its benchmark placements: the drug-design results attributed to Mythos 5 do not establish a benefit a general Fable buyer will receive.